Shares Magazine shines a spotlight on N4 Pharma (N4P:AIM), revolutionising biotech with advanced delivery systems for nucleic acids in oncology, gene therapy, and vaccines. Our patented mesoporous silica nanoparticles and newly acquired lipid-peptide delivery platform ensure precise, targeted treatment.

We aim to become a leading supplier to major pharma and biotech companies, currently pursuing orphan drug designation and pre-IND approval.

Discover our breakthroughs and engage with us on our interactive investor hub. Submit your questions via the ‘Ask a question’ button and be part of our journey to transform medicine.

Read the full article here:

Sign up to the N4 investor hub so you don’t miss out on future company news here.